Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by research analysts at William Blair to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Other analysts have also issued reports about the stock. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, January 21st. JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They issued an “overweight” rating for the company.

Zealand Pharma A/S Stock Down 0.7 %

OTCMKTS ZLDPF opened at $97.78 on Thursday. Zealand Pharma A/S has a 52 week low of $80.86 and a 52 week high of $141.74. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The business’s fifty day simple moving average is $101.00 and its 200-day simple moving average is $112.64. The firm has a market cap of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. As a group, equities analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.